Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Chengdu MedGenCell

Company type: Therapeutics

Main focus: Gene editing for the development of cellular therapies

Company stage: Clinical

Diseases: Haematological and solid tumours

Genome-editing tool: CRISPR

Funding stage: Private

Location: Chengdu, China

Website: http://www.medgencell.com/

Shanghai IASO Biotechnology develops next-generation CAR-T cell therapies, and uses CRISPR to knock out certain genomic targets to improve the efficacy and safety of its cellular products.

Chengdu MedGenCell, Co., Ltd.

Press Releases

Related News and Updates

Job Opportunities

Clinical Trials

Pre-clinical Trials

Stocks and Markets

Diseases

Webinar

Your Latest CMN News

CMN Weekly (17 January 2025) - Your Weekly CRISPR...

CMN Weekly

Jan. 17, 2025

Some of the best links we picked up around the internet

CRISPR Medicine in 2024 - A Recap

CMN Special

Jan. 15, 2025

2024 was a fantastic year for the CRISPR Medicine community. In this piece, we look back on some highlights from the year.

CRISPR/CasRx-Mediated Silencing of HTT Shows...

CMN Briefs

Jan. 14, 2025

Researchers in China report that targeting mutant HTT RNA with CRISPR/CasRx reduces the expression of diseased huntingtin protein and improves...

CMN Weekly (10 January 2025) - Your Weekly CRISPR...

CMN Weekly

Jan. 10, 2025

Some of the best links we picked up around the internet

Tune Therapeutics' HBV Epigenetic Silencer:...

CMN Clinical

Jan. 8, 2025

Tune Therapeutics has announced regulatory approval to begin a Phase 1b trial of its chronic hepatitis B therapy in Hong Kong, marking a strategic...

CRISPR Interference Reduces Antibiotic Resistance